PF-06671008 Dose Escalation Study in Advanced Solid Tumors

A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.

Key Inclusion Criteria

• Diagnosis of tumor type with the potential to have P-cadherin expression that is resistant to standard therapy or for which no standard therapy is available
• Performance status of 0 or 1
• Adequate bone marrow, kidney and liver function

Key Exclusion Criteria

• Known CNS disease including, but not limited to, metastases
• Current or history of seizure disorder
• History of or active autoimmune disorders
• Active bacterial, fungal or viral infection
• Major surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study treatment
• Requirement for systemic immune suppressive medication
• Grade 2 or greater peripheral neuropathy